Bionano Genomics, Inc. 8K

Bionano furnished an investor presentation dated September 14, 2026 describing the clinical adoption and reimbursement progress of its OGM platform, recent Q2 2026 financial outperformance, debt retirement, and a multi‑year outlook for revenue growth and margin improvement, all presented as forward‑looking statements subject to substantial risk factors.

On September 14, 2026, Bionano, led by Chairman and Interim CEO Albert Luderer, PhD, provided an investor presentation outlining the company’s strategic and financial transformation around its optical genome mapping (OGM) platform, including extensive discussion of forward‑looking expectations for revenue growth, margin improvement, operating expense reductions, and a projected path to adjusted EBITDA breakeven by Q4 FY 2027. The presentation highlighted market adoption and clinical validation of OGM, recent and upcoming reimbursement catalysts such as the establishment of two AMA CPT codes (81195 for hematologic malignancies and 81354 for constitutional genetic disorders) with 2026 payment rates, and the August 27, 2026 MolDX draft local coverage determination for OGM in hematologic malignancies. Management reported Q2 2026 performance metrics including revenue of $8.2 million (above prior guidance), record flow cell sales, improved adjusted gross margin, reduced adjusted operating expenses, retirement of JGB debt that had been secured by $10.3 million of restricted cash, and raised the lower end of FY 2026 revenue guidance to $31–33 million. Bionano also described the financial impact of its 2023–2025 restructuring and cost‑savings program, the discontinuation of its legacy Lineagen business, the concentration of consumables revenue among routine‑use OGM customers, and longer‑term outlook through FY 2029 for revenue growth, gross margin expansion, and increasing flow cell utilization, while emphasizing that these projections are subject to significant risks and uncertainties as detailed in its SEC filings.

Filing Facts

CIK

1411690

Ticker

-

Form

8K

Source Type

sec

Accession

0001411690-26-000046

Alert Tier

6